MX2024013313A - Uso de inhibidor de miostatina para tratar la atrofia muscular espinal - Google Patents
Uso de inhibidor de miostatina para tratar la atrofia muscular espinalInfo
- Publication number
- MX2024013313A MX2024013313A MX2024013313A MX2024013313A MX2024013313A MX 2024013313 A MX2024013313 A MX 2024013313A MX 2024013313 A MX2024013313 A MX 2024013313A MX 2024013313 A MX2024013313 A MX 2024013313A MX 2024013313 A MX2024013313 A MX 2024013313A
- Authority
- MX
- Mexico
- Prior art keywords
- muscular atrophy
- spinal muscular
- treating spinal
- myostatin inhibitor
- myostatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364188P | 2022-05-04 | 2022-05-04 | |
| US202263366447P | 2022-06-15 | 2022-06-15 | |
| US202263366662P | 2022-06-20 | 2022-06-20 | |
| US202263378987P | 2022-10-10 | 2022-10-10 | |
| PCT/US2023/020843 WO2023215384A2 (en) | 2022-05-04 | 2023-05-03 | Use of myostatin inhibitor for treating spinal muscular atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013313A true MX2024013313A (es) | 2025-02-10 |
Family
ID=86732326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013313A MX2024013313A (es) | 2022-05-04 | 2024-10-28 | Uso de inhibidor de miostatina para tratar la atrofia muscular espinal |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250326827A1 (enExample) |
| EP (1) | EP4518970B1 (enExample) |
| JP (1) | JP2025514978A (enExample) |
| KR (1) | KR20250021401A (enExample) |
| CN (1) | CN119451696A (enExample) |
| AU (1) | AU2023265846A1 (enExample) |
| CA (1) | CA3251441A1 (enExample) |
| DK (1) | DK4518970T3 (enExample) |
| FI (1) | FI4518970T3 (enExample) |
| IL (1) | IL316463A (enExample) |
| LT (1) | LT4518970T (enExample) |
| MX (1) | MX2024013313A (enExample) |
| WO (1) | WO2023215384A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2026076383A1 (en) * | 2024-10-06 | 2026-04-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| WO2008127722A1 (en) | 2007-04-12 | 2008-10-23 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| KR20210082548A (ko) * | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| PL4232151T3 (pl) * | 2020-10-26 | 2026-02-23 | Scholar Rock, Inc. | Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni |
| BR112023015177A2 (pt) | 2021-01-29 | 2023-11-14 | Biocad Joint Stock Co | Ácido nucleico compreendendo smn1 e mir-23a para tratamento da atrofia muscular espinhal, cassete de expressão, vetor de expressão, vírus recombinante, composição farmacêutica, uso e método relacionados |
-
2023
- 2023-05-03 CA CA3251441A patent/CA3251441A1/en active Pending
- 2023-05-03 CN CN202380045672.1A patent/CN119451696A/zh active Pending
- 2023-05-03 KR KR1020247040101A patent/KR20250021401A/ko active Pending
- 2023-05-03 WO PCT/US2023/020843 patent/WO2023215384A2/en not_active Ceased
- 2023-05-03 AU AU2023265846A patent/AU2023265846A1/en active Pending
- 2023-05-03 IL IL316463A patent/IL316463A/en unknown
- 2023-05-03 EP EP23729539.9A patent/EP4518970B1/en active Active
- 2023-05-03 LT LTEPPCT/US2023/020843T patent/LT4518970T/lt unknown
- 2023-05-03 JP JP2024563648A patent/JP2025514978A/ja active Pending
- 2023-05-03 US US18/862,079 patent/US20250326827A1/en active Pending
- 2023-05-03 DK DK23729539.9T patent/DK4518970T3/da active
- 2023-05-03 FI FIEP23729539.9T patent/FI4518970T3/fi active
-
2024
- 2024-10-28 MX MX2024013313A patent/MX2024013313A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023215384A2 (en) | 2023-11-09 |
| AU2023265846A1 (en) | 2024-12-12 |
| IL316463A (en) | 2024-12-01 |
| EP4518970A2 (en) | 2025-03-12 |
| CA3251441A1 (en) | 2023-11-09 |
| JP2025514978A (ja) | 2025-05-13 |
| LT4518970T (lt) | 2026-04-27 |
| CN119451696A (zh) | 2025-02-14 |
| WO2023215384A3 (en) | 2023-12-07 |
| EP4518970B1 (en) | 2026-03-25 |
| US20250326827A1 (en) | 2025-10-23 |
| KR20250021401A (ko) | 2025-02-12 |
| DK4518970T3 (da) | 2026-04-07 |
| FI4518970T3 (fi) | 2026-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0609429B8 (pt) | uso de uma solução aquosa com potencial de oxirredução (orp) | |
| WO2023215384A3 (en) | Use of myostatin inhibitor for treating spinal muscular atrophy | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| WO2009104178A3 (en) | A skin treatment apparatus for personal use and method for using same | |
| PE20010925A1 (es) | Compuestos inhibidores del neuropeptido y utiles para el tratamiento de la disfuncion sexual femenina | |
| MX2023002235A (es) | Dispositivo para el tratamiento de la piel. | |
| MX2024011142A (es) | Tratamiento de neurofibromas cutaneos con mirdametinib. | |
| MX2022014584A (es) | Composiciones y métodos relacionados con la piel envejecida. | |
| BR112022018115A2 (pt) | Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais | |
| GEP20125432B (en) | Improved testosterone gel and use thereof | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| EA200870086A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства | |
| MX2023004763A (es) | Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| MX2024015041A (es) | Fitusiran para el tratamiento de la hemofilia a y b | |
| NO20062336L (no) | Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander | |
| BR112021017198A2 (pt) | Uso de vibegron para tratar bexiga hiperativa | |
| MX2022003442A (es) | Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas. | |
| WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
| BR112022015502A2 (pt) | Tratamento da infecção por coronavírus com interferon lambda | |
| MX2022011138A (es) | Efecto contra coronavirus y aplicacion de inhibidor de fosfatidilinositol 4-cinasa. | |
| JOP20240156A1 (ar) | طريقة لعلاج الداء النشواني al | |
| AR050626A1 (es) | Composicion quimica y metodo para tratar desorden gastrointestinal | |
| BR112023024746A2 (pt) | Composto inibidor de iodotironina desiodase tipo 2, e, composição farmacêutica | |
| BRPI0408892A (pt) | uso de timosina alfa 1 para tratar as infecções por arpergillus |